Paradigm Biopharmaceutica Company Top Insiders

Paradigm Biopharmaceutica Management Team Effectiveness

The company has return on total asset (ROA) of (0.4422) % which means that it has lost $0.4422 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.651) %, meaning that it generated substantial loss on money invested by shareholders. Paradigm Biopharmaceutica's management efficiency ratios could be used to measure how well Paradigm Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities. Paradigm Biopharmaceutica owns a total of 282.24 Million outstanding shares. Paradigm Biopharmaceutica holds 16.46 pct. of its outstanding shares held by insiders and 18.7 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in pink sheets such as Paradigm Biopharmaceutica in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Paradigm Biopharmaceutica, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Paradigm Biopharmaceutica Workforce Comparison

Paradigm Biopharmaceutica Benchmark Summation

Paradigm Biopharmaceutica Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Paradigm Biopharmaceutica often depends on how effective the management is. Paradigm Biopharmaceutica management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Paradigm management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Paradigm management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

When running Paradigm Biopharmaceutica's price analysis, check to measure Paradigm Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Paradigm Biopharmaceutica is operating at the current time. Most of Paradigm Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Paradigm Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Paradigm Biopharmaceutica's price. Additionally, you may evaluate how the addition of Paradigm Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.